Adneuris licenses cebranopadol to Conba for Greater China pain market
Adneuris Therapeutics, a subsidiary of privately held Tris Pharma, has signed an exclusive licence agreement with Shanghai-listed Zhejiang Conba Pharmaceutical granting the Chinese firm rights to develop and commercialise cebranopadol for acute pain across mainland China, Hong Kong, Macao and Taiwan.
Under the terms of the deal, Conba pays a $17.5 million upfront fee, with development and commercial milestone payments that could exceed $100 million in total, plus tiered royalties on net sales beginning in the double digits. Conba also holds an option to expand into additional indications, including cancer pain and chronic pain. Adneuris described the transaction as its first licensing deal outside the United States.
The deal
Cebranopadol is a dual agonist targeting two receptors: the nociceptin/orphanin FQ peptide receptor and the µ-opioid peptide receptor. The company positions it as a first-in-class agent, arguing that the dual mechanism may deliver comparable pain relief to conventional opioids while reducing the risks of dependence, misuse and overdose. The candidate completed two pivotal Phase 3 trials, ALLEVIATE-1 and ALLEVIATE-2, in post-surgical pain settings involving abdominoplasty and bunionectomy respectively. Combined, cebranopadol's clinical programme enrolled more than 2,400 participants, and both pivotal studies reportedly showed statistically significant pain reduction versus placebo over 48 hours, with lower use of opioid rescue medication.
Adneuris plans to submit a New Drug Application to the FDA before the end of this year for the acute pain indication. The FDA has separately granted Fast Track Designation to cebranopadol for chronic low back pain.
Ketan Mehta, founder and chief executive of Tris Pharma, said the partnership was shaped by Conba's "deep commercial infrastructure and clinical relationships across China's hospital system and physician networks," adding that the goal was to offer patients "a new potential option in pain management" beyond traditional opioids.
Market context
China's analgesic and postoperative pain management market is sizeable and, by most assessments, under-served relative to Western markets, partly because opioid prescribing is tightly controlled and stigmatised. That regulatory and cultural backdrop makes a non-opioid or reduced-dependence analgesic an attractive commercial proposition, provided it can navigate the National Medical Products Administration's approval pathway, which typically requires local clinical data.
Conba brings institutional weight: it is listed on the Shanghai Stock Exchange, backed by state-owned Zhejiang International Trade Group, and ranks among China's top ten traditional Chinese medicine enterprises. That combination of regulatory connectivity and hospital-system reach is a common rationale for selecting a Chinese partner with established infrastructure over building a local operation from scratch.
Globally, the non-opioid analgesic space has drawn significant pharmaceutical interest following years of regulatory and public-health pressure on conventional opioids. Several companies are pursuing mu-opioid receptor partial agonists, sodium-channel blockers and other novel mechanisms. Cebranopadol's dual-receptor approach is differentiated in mechanism, though the asset will need to demonstrate a clean safety signal in post-NDA pharmacovigilance to sustain that positioning.
The NIH's National Institute on Drug Abuse has also awarded Tris a five-year grant of up to $16.6 million to study cebranopadol's potential in opioid use disorder, broadening the programme's optionality beyond acute pain. That government-backed programme could add data credibility ahead of anticipated commercial launch, and may strengthen the case for label expansions in China if Conba exercises its option to pursue additional indications.